ABVC BioPharma (NASDAQ:ABVC) Trading Up 1.5% – Still a Buy?

ABVC BioPharma, Inc. (NASDAQ:ABVC) traded up 1.5% during mid-day trading on Thursday . The stock traded as high as $2.11 and last traded at $2.08. 50,801 shares were traded during mid-day trading, an increase of 1% from the average session volume of 50,541 shares. The stock had previously closed at $2.05.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ABVC BioPharma in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, ABVC BioPharma currently has an average rating of “Sell”.

ABVC BioPharma Stock Down 1.0%

The firm has a 50-day moving average of $2.31 and a 200 day moving average of $2.78. The stock has a market capitalization of $50.06 million, a P/E ratio of -10.30 and a beta of 0.21.

ABVC BioPharma (NASDAQ:ABVC) last announced its quarterly earnings results on Friday, October 31st. The company reported ($0.05) earnings per share (EPS) for the quarter. The business had revenue of $0.80 million for the quarter.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ABVC. Geode Capital Management LLC boosted its holdings in ABVC BioPharma by 5.8% during the second quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock valued at $246,000 after purchasing an additional 6,017 shares in the last quarter. Millennium Management LLC acquired a new position in shares of ABVC BioPharma in the 3rd quarter worth approximately $60,000. Finally, Citadel Advisors LLC bought a new position in shares of ABVC BioPharma during the 3rd quarter worth approximately $48,000. Institutional investors and hedge funds own 11.38% of the company’s stock.

ABVC BioPharma Company Profile

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.